O -Phosphoserine (Sep) was identified 80 years ago as a constituent of phosphoproteins from egg yolk (1) . Since then, the extent and importance of the eukaryotic phosphoproteome has been realized and has provided insight into large interconnected networks of kinases and phosphatases (2) . Protein kinases represent one of the largest eukaryotic gene families, composing nearly 2% of all human genes (3) . Sep is the most abundant phosphoamino acid; based on an analysis of >2000 HeLa cell phosphoproteins, the relative abundance of Sep is 7.3 and 48 times higher than that of phosphothreonine and phosphotyrosine, respectively (2) . A major research limitation is the inability to biosynthesize these phosphoproteins for detailed studies of their enzyme or substrate properties.
The discovery of Sep-tRNA synthetase (SepRS), a unique aminoacyl-tRNA synthetase devoted to Sep-tRNA Cys formation in methanogenic archaea, provided an opportunity to develop our Sep-insertion strategy. The natural role of SepRS is the formation of Sep-tRNA Cys , which is then converted to Cys-tRNA Cys by the enzyme SepCysS in the presence of a sulfur donor (4) (Fig. 1A) . Given the high specificity of SepRS for Sep and for tRNA Cys and our knowledge of the identity elements in this tRNA (5) , and based on our understanding of the structure of this enzyme and its catalytic site (6, 7), we devised a system to incorporate Sep into proteins directed by the UAG (amber) codon. For this, we chose Methanocaldococcus jannaschii (Mj) tRNA
Cys and the mesophilic Methanococcus maripaludis (Mmp) SepRS as the orthogonal pair [reviewed in (8) ] for the synthesis of phosphoserylated amber suppressor tRNA.
We first designed tRNA Sep (Fig. 1B) , an amber suppressor tRNA derived from Mj tRNA Cys by two mutations in the anticodon, and an additional C20U change that improves aminoacylation by SepRS (5) . In vitro aminoacylation by Mmp SepRS showed (Fig. 1C) that the anticodon change lowered (to about 40%) the ability of tRNA Sep to be aminoacylated when compared to tRNA Cys . In agreement with earlier data (5), total Escherichia coli tRNA could not be acylated with Sep (Fig. 1C) (Fig. 2) . When only tRNA Sep was expressed (Fig. 2, column B) , Cm resistance increased about 3.3-fold over background (Fig. 2,  column A) . Thus, tRNA
Sep can be aminoacylated to a certain degree by an unknown E. coli aminoacyl-tRNA synthetase (we later found that Gln is being incorporated at the amber stop codon). In contrast, simultaneous expression of tRNA Sep and SepRS did not provide Cm resistance (Fig. 2, column C) . This may indicate that SepRS can outcompete any endogenous aminoacyl-tRNA synthetase and form Sep-tRNA Sep ; however, this aminoacyl-tRNA is neither delivered to the ribosome nor accommodated on it. Providing additional EF-Tu did not improve the result (Fig. 2, column D (4) . Indeed, a 2.3-fold increase in Cm resistance was observed (Fig. 2, column E) . This further supports the notion that although Sep-tRNA Sep is synthesized, it cannot be used properly by the E. coli protein biosynthesis machinery. By contrast, coexpression of tRNA Sep and Mmp CysRS generated a 12.3-fold increase in Cm resistance (Fig 2, column F significantly deacylated irrespective of the presence of EF-Tu ( Fig. 3B and fig. S1 ). Thus, insufficient binding of Sep-tRNA Sep to EF-Tu may explain the lack of Sep insertion into protein.
This observation required the generation of EF-Tu variants able to productively bind Sep-tRNA. We were encouraged by reports that EF-Tu variants allow binding of tRNAs charged with certain unusual amino acids (15, 16) . Guided by the structure of the E. coli EF-Tu:Phe-tRNA Phe complex (17) Fig. 3A ), led to a 10-fold increase in Cm resistance (Fig. 2 , column H), whereas the combination of SepRS and EF-Sep without tRNA Sep was not active in the CAT suppression assay (Fig. 2 , column G). Thus, it appeared that EF-Sep did bind Sep-tRNA Sep , a conclusion that was confirmed in the hydrolysis protection assay (Fig.  3B ). This assay also shows that EF-Sep still retained some ability to bind Cys-tRNA ( fig. S1 ).
To prove that the observed suppression is due to Sep incorporation, we expressed myoglobin with an amber codon in the Asp 127 position ( fig.  S2A ). The expected full-length protein was synthesized only when EF-Sep, SepRS, and tRNA Sep were coexpressed ( fig. S2A ). Mass spectrometrytime-of-flight (MS-TOF) and MS/MS analysis showed that Sep is present at the position specified by UAG in both the intact and trypsindigested proteins (Fig. S2, B and C) .
Final validation of our strategy was the synthesis of a Sep-containing human protein MEK1 (mitogen-activated ERK activating kinase 1). This key eukaryotic enzyme of the mitogen-activated (Fig. 4A) . MS/MS analysis confirmed the incorporation of Sep at position 218 (Fig. 4B) . To determine if our E. coli expression system would allow the simultaneous insertion of two Sep residues into the protein, we changed the Ser codons in positions 218 and 222 to UAG. As expected, the expression efficiency of MBP-MEK1(Sep 218 ,Sep 222 ) was markedly reduced compared to that of wild-type MBP-MEK1 (only about 1 mg of full-length protein was obtained from 1 liter of culture). The presence of Sep at both active-site positions of MEK1 was tested by Western blot analysis with a monoclonal antibody specific to phosphorylation at these two residues (Fig 4C) , and EF-Sep endows E. coli with the ability to read UAG as a phosphoserine codon.
Our work underscores the key role of EF-Tu in quality control of protein synthesis by ensuring facile delivery of the correct cognate aminoacyltRNA to the ribosome (10, 20) . Generating an orthogonal aminoacyl-tRNA synthetase:tRNA pair was insufficient to genetically encode Sep. Expansion of the genetic code to include Sep depended critically on reengineering of EF-Tu to bind Sep-tRNA Sep . This situation is precisely paralleled in the naturally evolved genetic encoding system for selenocysteine, which requires a specialized elongation factor [SelB in prokaryotes, and EFSec in eukaryotes; reviewed in (21)]. Inspired careful manipulation of components of the protein-synthesizing system will allow further expansion of the genetic code without sacrificing organismal fitness.
Orthogonal aminoacyl-tRNA synthetase:tRNA pairs (in our case, SepRS:tRNA Sep ) are critical elements for genetic code expansion, whether produced by evolutionary processes and found in nature [e.g., pyrrolysyl-tRNA synthetase:tRNA Pyl (22) ] or designed in the laboratory by synthetic biologists [reviewed in (8) ]. The tRNA of choice is typically an amber suppressor tRNA; however, a general limitation in product yield is associated with recoding the new amino acid by a stop codon (e.g., UAG), because peptide chain elongation by the designed aminoacylated suppressor tRNA competes with chain termination by the release factor (e.g., RF1
). Yet this impediment may soon be removed by the advent of E. coli expression strains with genome-wide UAG codon reassignments and an RF1 deletion (23, 24) .
The ability to generate physiologically relevant active kinases and stoichiometrically phosphorylated protein domains could reveal new types of kinase inhibitors for drug development, allow systematic dissection of phosphorylationdependent protein-protein interactions, and expose new structure-function relationships (18, 25, 26) . Synthetase" by D. Soll and J. Rinehart. Yale University has applied for a patent that covers the engineered EF-Tu described in this manuscript. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide.
To explore the genetic origins of this cancer, we used whole-exome sequencing and gene copy number analyses to study 32 primary tumors. Tumors from patients with a history of tobacco use had more mutations than did tumors from patients who did not use tobacco, and tumors that were negative for human papillomavirus (HPV) had more mutations than did HPV-positive tumors. Six of the genes that were mutated in multiple tumors were assessed in up to 88 additional HNSCCs. In addition to previously described mutations in TP53, CDKN2A, PIK3CA, and HRAS, we identified mutations in FBXW7 and NOTCH1. Nearly 40% of the 28 mutations identified in NOTCH1 were predicted to truncate the gene product, suggesting that NOTCH1 may function as a tumor suppressor gene rather than an oncogene in this tumor type.
M ore than half a million new cases of head and neck squamous cell carcinoma (HNSCC) will occur in 2011, including 50,000 cases in the United States, making it the sixth most common cancer in the world (1-3). HNSCC and its treatment can result in cosmetic deformity and functional impairment of vital functions, including breathing, swallowing, speech, phonation, taste, hearing, and smell. These cancers are frequently lethal, with a fiveyear survival of only~50% (4) . HNSCCs, like all solid tumors, are thought to be initiated and to progress through a series of genetic alterations. Indeed, several cellular signaling pathways are dysregulated in this tumor type through genetic and epigenetic alterations, such as those involving TP53 and CDK2NA (4). HNSCCs also exhibit many chromosomal abnormalities, including amplifications of region 11q13, which contains the cyclin D1 gene, and region 7p11, which encodes epidermal growth factor receptor (EGFR) (5) . Tobacco use and excessive alcohol consumption are major risk factors for HNSCC in the United States (6). More recently, human papillomavirus (HPV) has emerged as an additional risk factor for the development of cancers of the oropharynx (7). Patients with HPV-associated cancers have an improved overall and disease-specific survival, suggesting that these tumors have distinct biological features (8) .
To gain a comprehensive view of the genetic alterations underlying HNSCC, we sequenced 18,000 protein-encoding genes in tumors from 32 patients. Thirty of the 32 patients had not been treated with chemotherapy or radiation before their tumor biopsy, so the spectrum of changes we observed largely reflects those of tumors in their naturally occurring state. Tumor samples were carefully selected or microdissected in order to achieve a neoplastic cellularity of >60%. DNA was purified from these tumors as well as matched nonneoplastic tissue and used to generate libraries suitable for massively parallel sequencing. After capture of the coding sequences with a SureSelect (Agilent, Santa Clara, California) or CCDS (NimbleGen, Madison, Wisconsin) Enrichment System, the DNAwas sequenced by using an Illumina (San Diego, California) GAIIx/HiSEq (17 tumors) or SOLiD (Carlsbad, California) V3/V4 (15 tumors) instruments. The average coverage of each base in the targeted regions was 77-fold and 44-fold for the Illumina and SOLiD instruments, and 92.6% and 90% of targeted bases were represented by at least 10 reads in these platforms, respectively (table S1).
Using stringent criteria for analysis of these data (9), we identified 911 candidate somatic mutations in 725 genes among the 32 tumors. To ensure that our algorithms for identifying mutations were reliable, we evaluated the candidate mutations by Sanger sequencing or by 454 sequencing and confirmed 609 of them (67%) (table S2). One hundred and fifty-two (17%) mutations did not confirm, and 150 (16%) mutations could not be tested because of an unusually high GC content, difficulty in the design of unique primers, or other unknown factors preventing specific amplification and sequencing of the locus. The range of confirmed mutations per tumor was 2 to 78, with a mean and SD of 19 T 16.5 mutations per tumor (table S1) .
There were obvious differences in the genetic landscapes of HPV-associated and HPV-negative HNSCCs. First, far fewer genes were mutated per tumor in the HPV-associated tumors as compared with those tumors not epidemiologically related 
